SCHEMBL4366293

SCHEMBL4366293

N[N+]12C=CN=CC1=C(c1cccc(O)c1)N=C2c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 1/20 0.38
GPR84 Q9NQS5 1/20 0.34
CHEK2 O96017 1/20 0.33
XDH P47989 1/20 0.33
LTA4H P09960 1/20 0.33
NR1H2 P55055 1/20 0.33
BAX Q07812 1/20 0.33
HSD17B1 P14061 3/20 0.32
HSD17B2 P37059 3/20 0.32
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31
PTPN1 P18031 1/20 0.31
CYP3A4 P08684 2/20 0.31
CYP2C9 P11712 2/20 0.31
MCL1 Q07820 1/20 0.31
GRIN1 Q05586 1/20 0.30
GRIN2B Q13224 1/20 0.30
ESR1 P03372 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4363018 0.89 LTA4H (0.42) TNK2GPR84XDHLTA4HNR1H2
SCHEMBL1131147 0.89 NPC1 (0.34) TNK2CHEK2XDHLTA4HMCL1
SCHEMBL4368285 0.88 MAOB (0.40) TNK2CHEK2XDH
SCHEMBL4360821 0.87 TNK2 (0.38) TNK2LTA4HNR1H2CYP3A4CYP2C9
SCHEMBL4370412 0.87 AKR1C3 (0.42) TNK2CHEK2MCL1
SCHEMBL4352476 0.86 PARP10 (0.42) TNK2CHEK2MCL1
SCHEMBL4364188 0.85 TNK2 (0.41) TNK2CHEK2
SCHEMBL4352081 0.83 MAOA (0.43) TNK2CHEK2XDHCYP3A4CYP2C9
SCHEMBL4353437 0.82 MAPK14 (0.36) TNK2XDHLTA4HCYP3A4
SCHEMBL4357979 0.82 LTA4H (0.42) TNK2LTA4HMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US claimed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP claimed
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 TNK2 2837/4885GPR84 2408/4885CHEK2 1900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.